Selected current ongoing cooperative group clinical trials.
| Group . | Population . | Strategy . |
|---|---|---|
| Abbreviations: CALGB, Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; SWOG, Southwest Oncology Group; MRC, Medical Research Council; GAMLCG, German Acute Myeloid Leukemia Cooperative Group; HSCT, hematopoietic stem cell transplantation; IL, interleukin; DA, daunorubicin and cytarabine; ind, induction; consol, consolidation; TAD, 6-thioguanine, cytarabine, daunorubicin; HAM, high-dose cytarabine and mitoxantrone; Main, maintenance; ASCT, autologous stem cell transplant; HDAC, high-dose cytarabine; Obs, observation; GO, gemtuzumab ozogamicin; IA, idarubicin, cytarabine; Mitox, mitoxantrone; MUD, matched unrelated donor; ASMA/A, amsacrine/cytarabine | ||
| CALGB | Younger | Chemo +/− PSC-833 (closed 8/03) followed by HSCT +/− IL-2 DA, HDAC +/− Genasense |
| CALGB | Older | |
| ECOG | Older | DA ind/consol +/− Zosuquidar |
| ECOG | Younger | Dauno 45 vs 90 mg/m2 + HDAC; +/− GO before ASCT |
| SWOG | Older | DA + Cyclosporine A |
| SWOG | Younger | DA + GO; HDAC consol; +/− GO maintenance |
| US Intergroup | Older | Zarnestra |
| US Intergroup | All | Zarnestra vs Obs in CR2 or higher CR |
| MRC | Older | Intensive (DA, 3 vs 4 courses of consol) vs nonintensive (LoDAC +/− GO) |
| GAMLCG | Younger | TAD/HAM vs HAM/HAM, TAD consol, Maint vs ASCT |
| GAMLCG | Older | TAD/HAM vs HAM/HAM (A 1 g/m2)(Cycle 2 if day 16 blasts > 5%) |
| HOVON | Younger | IA (200 vs 1000 g/m2), AMSA/A (1 vs 2 g/m2) consol, Mitox/Etoposide vs ASCT (Fav-risk), Allo (Intermediate risk), MUD (Unfavorable risk) |
| HOVON | Older | Dauno 45 vs 90 mg/m2 + consol; GO maintenance vs obs |
| EORTC/GIMEMA | Younger | DA (Std vs 3 g/m2 dose), DA (intermed dose) consol, ASCT then IL-2 vs Obs Maint |
| Group . | Population . | Strategy . |
|---|---|---|
| Abbreviations: CALGB, Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; SWOG, Southwest Oncology Group; MRC, Medical Research Council; GAMLCG, German Acute Myeloid Leukemia Cooperative Group; HSCT, hematopoietic stem cell transplantation; IL, interleukin; DA, daunorubicin and cytarabine; ind, induction; consol, consolidation; TAD, 6-thioguanine, cytarabine, daunorubicin; HAM, high-dose cytarabine and mitoxantrone; Main, maintenance; ASCT, autologous stem cell transplant; HDAC, high-dose cytarabine; Obs, observation; GO, gemtuzumab ozogamicin; IA, idarubicin, cytarabine; Mitox, mitoxantrone; MUD, matched unrelated donor; ASMA/A, amsacrine/cytarabine | ||
| CALGB | Younger | Chemo +/− PSC-833 (closed 8/03) followed by HSCT +/− IL-2 DA, HDAC +/− Genasense |
| CALGB | Older | |
| ECOG | Older | DA ind/consol +/− Zosuquidar |
| ECOG | Younger | Dauno 45 vs 90 mg/m2 + HDAC; +/− GO before ASCT |
| SWOG | Older | DA + Cyclosporine A |
| SWOG | Younger | DA + GO; HDAC consol; +/− GO maintenance |
| US Intergroup | Older | Zarnestra |
| US Intergroup | All | Zarnestra vs Obs in CR2 or higher CR |
| MRC | Older | Intensive (DA, 3 vs 4 courses of consol) vs nonintensive (LoDAC +/− GO) |
| GAMLCG | Younger | TAD/HAM vs HAM/HAM, TAD consol, Maint vs ASCT |
| GAMLCG | Older | TAD/HAM vs HAM/HAM (A 1 g/m2)(Cycle 2 if day 16 blasts > 5%) |
| HOVON | Younger | IA (200 vs 1000 g/m2), AMSA/A (1 vs 2 g/m2) consol, Mitox/Etoposide vs ASCT (Fav-risk), Allo (Intermediate risk), MUD (Unfavorable risk) |
| HOVON | Older | Dauno 45 vs 90 mg/m2 + consol; GO maintenance vs obs |
| EORTC/GIMEMA | Younger | DA (Std vs 3 g/m2 dose), DA (intermed dose) consol, ASCT then IL-2 vs Obs Maint |